Clinical Trial Update: Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating cabazitaxel in metastatic castration-resistant prostate cancer patients with AR-V7 positive circulating tumor cells.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Circulating Tumor Cell, Metastatic Prostate Cancer | Phase 2 | Status: UNKNOWN